Financial Results, Dividends, and Positive Outcome of Regulatory Inspection - Research Report on Waters, PAREXEL, PerkinElmer, NuVasive, and WuXi

NEW YORK, November 1, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Waters Corporation (NYSE: WAT), PAREXEL International Corporation (NASDAQ: PRXL), PerkinElmer, Inc., NuVasive, Inc. (NASDAQ: NUVA), and WuXi PharmaTech Cayman Inc. (NYSE: WX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Waters Corporation Research Report

On October 22, 2013, Waters Corporation (Waters) reported Q3 FY 2013 (period ended September 28, 2013) financial results. During the quarter, the Company's sales increased by 1.6% YoY to $457.3 million. Net income was $98.0 million or $1.14 per diluted common share in Q3 FY 2013, compared with $99.1 million or $1.12 per diluted common share in Q3 FY 2012. Douglas Berthiaume, Chairman, President, and CEO of Waters said, "Slower sales growth to our pharmaceutical base affected our overall top line performance. However, improved business conditions across our industrial chemical markets, in combination with stronger global governmental and academic demand, contributed to the sales growth in the quarter." The Full Research Report on Waters Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/2fff_WAT]

--

PAREXEL International Corporation Research Report

On October 29, 2013, PAREXEL International Corporation (PAREXEL) reported Q1 FY 2014 (period ended September 30, 2013) financial results. Total revenue during the quarter increased 14.4% YoY to $529.1 million. Net income was $26 million or $0.45 per diluted share in Q1 FY 2014, compared with $15.1 million, or $0.25 per diluted share in Q1 FY 2013. Josef H. von Rickenbach, Chairman and CEO of PAREXEL, said "In the first quarter, we drove continued improvement in our productivity and efficiency initiatives, while at the same time keeping a close eye on costs and proactively investing in the future on a targeted basis. This resulted in sequential and year-over-year improvements in gross margins across all three of our business segments, and significant improvement in operating margin. We achieved these results with a slightly lower than expected level of revenue caused by contract signature delays in the quarter, and typical seasonality patterns." For Q2 FY 2014, the Company anticipates revenue to be in the range of $475 million to $480 million and EPS to be between $0.46 and $0.50, while for full-year FY 2014, it expects revenue to be in the range of $1,890 million to $1,920 million and EPS to be between $1.95 and $2.11. The Full Research Report on PAREXEL International Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/067b_PRXL]

--

PerkinElmer, Inc. Research Report

On October 24, 2013, PerkinElmer, Inc. (PerkinElmer) announced that its Board of Directors has approved a regular quarterly dividend of $0.07 per share of common stock, payable on February 7, 2014, to all shareholders of record at the close of business as of January 17, 2014. The Full Research Report on PerkinElmer, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/2016_PKI]

--

NuVasive, Inc. Research Report

On October 29, 2013, NuVasive, Inc. (NuVasive) reported Q3 2013 financial results. During the quarter, the Company achieved revenue of $169.2 million, representing an increase of 14% YoY. Net income attributable to the Company was $7.5 million, or $0.16 per diluted share, in Q3 2013, compared with $2.4 million, or $0.05 per diluted share, in Q3 2012. Alex Lukianov, Chairman and CEO of NuVasive said, "The execution of our market share taking strategy has been outstanding through the first three quarters of 2013, and we are pleased to be increasing full year revenue and non-GAAP operating margin guidance to reflect solid outperformance. We are building on the momentum established at Eurospine and at NASS to close this year well and kick off 2014 with continued strategic execution." For full-year 2013, the Company anticipates revenue of c.$670 million, up from prior guidance of $655 million, and earnings EPS of c.$0.07, up from prior guidance of a loss per share of $0.09. The Full Research Report on NuVasive, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/c66c_NUVA]

--

WuXi PharmaTech Cayman Inc. Research Report  

On October 29, 2013, WuXi PharmaTech Cayman Inc. (WuXi) announced that the advanced intermediate manufacturing facility of the Company's subsidiary, Shanghai SynTheAll Pharmaceutical Co. Ltd (STA) and small molecule API has completed a general GMP and Pre-Approval Inspection from the U.S. Food and Drug Administration (FDA) with no Form 483 issued. The Company informed that the result of the inspection confirms STA's capabilities in helping the clients move their new chemical entities through clinical development stages and eventually to commercial launch in the global market. Dr. Ge Li, Chairman and CEO of WuXi, said "The result of this inspection speaks to WuXi's high standards of quality. We continue to leverage our knowledge and that of our partners to build and operate a first-class quality system in China that meets global regulatory requirements." The Full Research Report on WuXi PharmaTech CaymanInc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/df7b_WX]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner